Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Current Deferred Revenue: 2021-2024

Historic Current Deferred Revenue for Relay Therapeutics (RLAY) over the last 2 years, with Dec 2024 value amounting to $7.7 million.

  • Relay Therapeutics' Current Deferred Revenue was N/A to $7.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.7 million, marking a year-over-year change of. This contributed to the annual value of $7.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Relay Therapeutics' Current Deferred Revenue is $7.7 million, which was up 2,996.37% from $248,000 recorded in FY2021.
  • Relay Therapeutics' Current Deferred Revenue's 5-year high stood at $7.7 million during FY2024, with a 5-year trough of $248,000 in FY2021.
  • Over the past 1 years, Relay Therapeutics' median Current Deferred Revenue value was $7.7 million (recorded in 2024), while the average stood at $7.7 million.